



SUPPLEMENTARY FIGURES



Supplementary Figure 1. Effect of GV1001 on amyloid beta (Aβ)₁₋₄₂ and p-tau in the brain of 3xTg AD mice in a dose-dependent manner. To evaluate the dose responsiveness of GV1001, we injected 0.01 mg/kg and 1 mg/kg GV1001 into middle-aged 3xTg AD mice subcutaneously for two months, from 12 months to 14 months of age. The results showed that 1 mg/kg GV1001 had a stronger effect against Aβ₁₋₄₂ (A) and p-tau (B) in the brains of middle-aged 3xTg mice than 0.01 mg/kg.



Supplementary Figure 2. GV1001 has a strong effect on senescence in the brain of 3xTg AD mice in a dose-dependent manner. Injection of 1 mg/kg GV1001 showed stronger effect than 0.01 mg/kg against neurodegeneration (A, B), and senescence (C–F) in the brains of middle-aged 3xTg AD mice. Therefore, we used 1 mg/kg GV1001 in the main study.